NWBO NORTHWEST BIOTHERAPEUTICS INC
Pharmaceutical Preparations · OTC · SEC CIK 1072379 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY204.8%
TTM net income YoY55.8%
TTM EPS YoY50.0%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,608.8%
Net margin-1,388.8%
FCF margin-1,557.6%
EBITDA margin-1,517.8%
Returns
ROE—
ROA-74.3%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets160.8%
Debt / equity—
Current ratio0.03x
Interest coverage-4.89x
Cash quality & payout
Operating cash flow / net income1.09x
Accruals ratio6.6%
Payout ratio—
Capex / revenue45.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.38M | $1.38M | $1.93M | $1.68M | $1.00M |
| R&D expense | $28.79M | $34.89M | $27.73M | $35.51M | $20.31M |
| SG&A expense | $32.51M | $33.00M | $29.71M | $33.35M | $33.40M |
| Operating income | -$59.91M | -$66.51M | -$55.51M | -$67.18M | -$52.70M |
| Interest expense | $8.70M | $7.77M | $5.24M | $6.07M | $5.01M |
| Pretax income | -$60.70M | -$83.78M | — | — | — |
| Income tax | -$537,000 | $0 | $0 | $0 | $0 |
| Net income | -$60.16M | -$83.78M | -$62.60M | -$105.03M | $179.13M |
| EBITDA | -$57.85M | -$64.76M | -$53.98M | -$65.93M | -$52.38M |
| EPS (basic) | -0.04 | -0.07 | -0.06 | -0.10 | 0.21 |
| EPS (diluted) | -0.04 | -0.07 | -0.06 | -0.10 | -0.06 |
| Weighted avg. shares (diluted) | 1.46B | 1.24B | 1.12M | 1.02M | 1.01M |
| Balance sheet | |||||
| Cash & equivalents | $3.04M | $2.17M | $2.13M | $6.96M | $15.17M |
| Current assets | $5.52M | $4.06M | $4.12M | $9.43M | $17.29M |
| PP&E, net | $17.41M | $16.20M | $17.28M | $13.42M | $15.03M |
| Goodwill | $626,000 | $626,000 | $626,000 | $626,000 | $626,000 |
| Intangibles | $53.19M | $1.29M | — | — | — |
| Total assets | $81.29M | $26.73M | $27.86M | $31.32M | $40.16M |
| Current liabilities | $91.70M | $68.27M | $45.20M | $126.00M | $133.77M |
| Long-term debt | $60.04M | $62.68M | $40.79M | $21.53M | $32.40M |
| Total debt | $60.04M | $62.68M | $40.79M | $21.53M | $32.40M |
| Total liabilities | $128.86M | $105.71M | $74.92M | $136.37M | $164.15M |
| Shareholders' equity | -$60.28M | -$94.49M | -$65.77M | -$128.10M | -$123.99M |
| Net debt | $57.00M | $60.50M | $38.67M | $14.56M | $17.23M |
| Shares outstanding | 1.56B | 1.33B | 1.18B | 1.07B | 948.40M |
| Cash flow statement | |||||
| Operating cash flow | -$44.76M | -$57.02M | -$53.64M | -$52.77M | -$38.30M |
| Capital expenditure | $1.50M | $1.01M | — | — | — |
| Free cash flow | -$46.27M | -$58.03M | — | — | — |
| Investing cash flow | -$1.81M | -$1.01M | -$3.44M | -$2.90M | -$6.01M |
| Financing cash flow | $49.33M | $56.78M | $52.76M | $41.97M | $48.13M |
| Depreciation & amortization | $2.06M | $1.74M | $1.52M | $1.25M | $324,000 |
| Stock-based compensation | $1.21M | $3.46M | $4.41M | $12.30M | $15.57M |
Free plan shows the latest 5 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.